Some compounded semaglutide products are marketed with vitamin B12 or other added ingredients. Patients should understand that compounded semaglutide products are not FDA-approved finished drug products and are not reviewed by FDA for safety, effectiveness or quality before marketing.
Vitamin B12 may be added by some compounders for formulation or patient-specific reasons. FDA has specifically noted that the safety and effectiveness of combining semaglutide with added ingredients such as vitamin B12 have not been established. Adding B12 does not make compounded semaglutide equivalent or superior to an FDA-approved semaglutide product.
FDA states that compounded drugs should generally be used when a patient’s medical needs cannot be met by an FDA-approved drug. The national semaglutide injection shortage was declared resolved in 2025, so shortage-based routine copying of approved products is no longer the general pathway it once was. Compounding rules also restrict routine production of products that are essentially copies of commercially available drugs. Any compounded semaglutide should therefore be considered only when there is a legitimate patient-specific medical reason and the prescription complies with applicable federal and state compounding requirements.
FDA-approved semaglutide products have undergone review for a specific indication, formulation, manufacturing process and labeling. Compounded products do not undergo that same premarket review and should not be described as FDA-approved, generic Wegovy, generic Ozempic, or automatically equivalent to an approved product. Patients should also ask whether the formulation uses semaglutide base rather than salt forms such as semaglutide sodium or acetate, which FDA has specifically cautioned against for compounding.
Semaglutide treatment should include an appropriate medical evaluation, review of contraindications and medications, side-effect monitoring, nutrition support and follow-up.
See our Semaglutide Los Angeles page for treatment information.
